REG - N4 Pharma PLC - Patent Grant

N4 PharmaAnnouncement

19/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240119:nRSS2078Aa&default-theme=true

RNS Number : 2078A  N4 Pharma PLC  19 January 2024

19 January 2024

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Patent Grant

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to announce that the University of Queensland has
informed the Company that it has been notified by its Indian patent attorney
of the granting of its patent for Nuvec® in India.

 

The granted patent in India is for a composition of matter patent for the
particle itself as well as the manufacturing process relating to how the
particle is made and matches the patents granted in the USA, Canada, Europe,
Japan, Australia and China.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"The granting of this patent is a further indication of the strength of the
intellectual property we have licensed from the University of Queensland and
we now have all of the major global territories with granted patents for
Nuvec®."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                  Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub                    Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit                                                  https://investors.n4pharma.com/link/0y5nKe
                                                                      (https://investors.n4pharma.com/link/0y5nKe)
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                                     Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDVLFFZFLFBBB